{"title":"CircRNA GRAMD4诱导NBR1表达促进肾细胞癌自噬和免疫逃逸。","authors":"Mi Zhou, Minyu Chen, Zhousan Zheng, Qihao Li, Lican Liao, Yunfei Wang, Yi Xu, Guannan Shu, Junhang Luo, Taowei Yang, Jiaxing Zhang","doi":"10.1080/15548627.2025.2503560","DOIUrl":null,"url":null,"abstract":"<p><p>The tumor microenvironment (TME) in renal cell carcinoma (RCC) frequently exhibits significant immune cell infiltration. However, tumor cells often manage to evade immune surveillance. This study revealed the mechanism by which circular RNA <i>circGRAMD4</i> regulates <i>NBR1</i>. <i>CircGRAMD4</i> is markedly elevated in RCC, and its high levels are correlated with a poor prognosis. Notably, the absence of <i>circGRAMD4</i> has been demonstrated to result in a significant inhibition of renal cancer cell growth. This inhibition has been attributed to an enhanced anti-tumor immunity mediated by CD8<sup>+</sup> T cells. Mechanistically, <i>circGRAMD4</i> interacts with the RBM4 protein, stabilizing the autophagic cargo receptor <i>NBR1</i> mRNA. This interaction promotes <i>NBR1</i> expression, which in turn leads to the degradation of MHC-I molecules through macroautophagy/autophagy pathways. Consequently, this process affects renal cancer cell antigen presentation, induces CD8<sup>+</sup> T cell dysfunction, and contributes to tumor immune escape. Moreover, by inhibiting <i>circGRAMD4</i> and using immune checkpoint blockers (ICB), the immunosuppressive TME is altered to prevent tumor immune evasion, ultimately increasing the effectiveness of ICB treatment. The discovery highlights the significant impact of <i>circGRAMD4</i> on RCC immune escape and proposes that blocking <i>circGRAMD4</i> could serve as a promising immunotherapy strategy when combined with ICB to enhance patient outcomes.</p>","PeriodicalId":93893,"journal":{"name":"Autophagy","volume":" ","pages":"1-21"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CircRNA <i>GRAMD4</i> induces <i>NBR1</i> expression to promote autophagy and immune escape in renal cell carcinoma.\",\"authors\":\"Mi Zhou, Minyu Chen, Zhousan Zheng, Qihao Li, Lican Liao, Yunfei Wang, Yi Xu, Guannan Shu, Junhang Luo, Taowei Yang, Jiaxing Zhang\",\"doi\":\"10.1080/15548627.2025.2503560\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The tumor microenvironment (TME) in renal cell carcinoma (RCC) frequently exhibits significant immune cell infiltration. However, tumor cells often manage to evade immune surveillance. This study revealed the mechanism by which circular RNA <i>circGRAMD4</i> regulates <i>NBR1</i>. <i>CircGRAMD4</i> is markedly elevated in RCC, and its high levels are correlated with a poor prognosis. Notably, the absence of <i>circGRAMD4</i> has been demonstrated to result in a significant inhibition of renal cancer cell growth. This inhibition has been attributed to an enhanced anti-tumor immunity mediated by CD8<sup>+</sup> T cells. Mechanistically, <i>circGRAMD4</i> interacts with the RBM4 protein, stabilizing the autophagic cargo receptor <i>NBR1</i> mRNA. This interaction promotes <i>NBR1</i> expression, which in turn leads to the degradation of MHC-I molecules through macroautophagy/autophagy pathways. Consequently, this process affects renal cancer cell antigen presentation, induces CD8<sup>+</sup> T cell dysfunction, and contributes to tumor immune escape. Moreover, by inhibiting <i>circGRAMD4</i> and using immune checkpoint blockers (ICB), the immunosuppressive TME is altered to prevent tumor immune evasion, ultimately increasing the effectiveness of ICB treatment. The discovery highlights the significant impact of <i>circGRAMD4</i> on RCC immune escape and proposes that blocking <i>circGRAMD4</i> could serve as a promising immunotherapy strategy when combined with ICB to enhance patient outcomes.</p>\",\"PeriodicalId\":93893,\"journal\":{\"name\":\"Autophagy\",\"volume\":\" \",\"pages\":\"1-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Autophagy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15548627.2025.2503560\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autophagy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15548627.2025.2503560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CircRNA GRAMD4 induces NBR1 expression to promote autophagy and immune escape in renal cell carcinoma.
The tumor microenvironment (TME) in renal cell carcinoma (RCC) frequently exhibits significant immune cell infiltration. However, tumor cells often manage to evade immune surveillance. This study revealed the mechanism by which circular RNA circGRAMD4 regulates NBR1. CircGRAMD4 is markedly elevated in RCC, and its high levels are correlated with a poor prognosis. Notably, the absence of circGRAMD4 has been demonstrated to result in a significant inhibition of renal cancer cell growth. This inhibition has been attributed to an enhanced anti-tumor immunity mediated by CD8+ T cells. Mechanistically, circGRAMD4 interacts with the RBM4 protein, stabilizing the autophagic cargo receptor NBR1 mRNA. This interaction promotes NBR1 expression, which in turn leads to the degradation of MHC-I molecules through macroautophagy/autophagy pathways. Consequently, this process affects renal cancer cell antigen presentation, induces CD8+ T cell dysfunction, and contributes to tumor immune escape. Moreover, by inhibiting circGRAMD4 and using immune checkpoint blockers (ICB), the immunosuppressive TME is altered to prevent tumor immune evasion, ultimately increasing the effectiveness of ICB treatment. The discovery highlights the significant impact of circGRAMD4 on RCC immune escape and proposes that blocking circGRAMD4 could serve as a promising immunotherapy strategy when combined with ICB to enhance patient outcomes.